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Accepted 15 October 2012AbstractObjective: To compare the prognosis of patients with advanced-stage primary peritoneal serous papillary carcinoma (PSPC) or papillary serous
ovarian cancer (PSOC).
Materials and Methods: This was a retrospective caseecontrol study and included two study groups: one with stage III/IV PSPC (n ¼ 38)
patients and the other with PSOC (n ¼ 53) patients. Patients were matched for histologic subtype (serous tumor), tumor stage, tumor grade,
residual disease at the end of debulking surgery (primary or interval), and age (5 years).
Results: Mean age was significantly greater for patients with PSPC (63.03  11.88 years) than for patients with PSOC (55.92  12.56 years,
p ¼ 0.008). Optimal debulking surgery was performed initially in 71.9% of PSPC patients and 66.0% of PSOC patients. In addition, 93.9% of
PSPC patients and 92.3% of PSOC patients were treated with platinumepaclitaxel chemotherapy. The frequency of high-grade tumors was
significantly higher in the PSPC (100%) than in the PSOC group (68.3%; p < 0.001). Progression-free survival (PFS) was similar in the PSPC
[median 12 months, 95% confidence interval (CI) 7.3e16.7] and PSOC groups (median 16.7 months, 95% CI 12.9e20.4; p ¼ 0.470). Overall
survival was shorter in the PSPC (median 62 months, 95% CI 19.6e104.4) than in the PSOC group (median 77.5 months, 95% CI 69.7e85.2;
p ¼ 0.006, log-rank statistic).
Conclusion: PFS was similar for advanced-stage PSPC and PSOC patients. Since the PSPC patients tended to be older and have more high-grade
tumors, OS was shorter for PSPC than for POSC patients. Thus, management of the two types of cancer should not differ.
Copyright  2013, Taiwan Association of Obstetrics & Gynecology. Published by Elsevier Taiwan LLC. All rights reserved.
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Primary peritoneal serous papillary carcinoma (PSPC) is
a malignancy with diffuse involvement of the peritoneal sur-
faces while sparing or minimally involving the ovaries. It is
histologically indistinguishable from epithelial ovarian cancer
(EOC) and has similar clinical characteristics, spreading pat-
terns, response to treatment, and survival rates. Previous* Corresponding author. Department of Obstetrics and Gynecology, Taipei
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http://dx.doi.org/10.1016/j.tjog.2012.10.003reports have suggested that women with PSPC have epi-
demiological features similar to women with epithelial ovarian
cancer, with the exception of an older age at diagnosis and an
increased rate of obesity and lymph node spreading in stage III
or IV primary PSPC [1].
There are numerous reports of very small series of patients
with this disease, but larger series are rare. The study with the
largest series (74 patients) was published 14 years ago [2].
This important study revealed the characteristics of patients
with PSPC. Other retrospective studies compared the prog-
nosis of PSPC to that of EOC [3e5]. To give more weight to
the relevance of these retrospective studies, a few teams
reported caseecontrol studies that evaluated PSPC prognosiscs & Gynecology. Published by Elsevier Taiwan LLC. All rights reserved.
Table 1
Patient characteristics.
PSPC PSOC p
All patients 38 53
Age (y) 63.03  11.88 55.92  12.56 0.008
FIGO stage
IIIC 31 (81.6) 46 (86.8) 0.497
IV 7 (18.4) 7 (13.2)
Histological type
Papillary serous 38 (100) 53 (100) 1.000
Grade
G2 0 (0) 13/41 (31.7) <0.001
G3 38 (100) 28/41 (68.3)
Cytoreduction
Optimal 23/32 (71.9) 35 (66.0) 0.575
Suboptimal 9/32 (28.1) 18 (34.0)
CA-125
Positive 30/31 (96.8) 39/41 (95.1) 0.998
Negative 1/31 (3.2) 2/41 (4.9)
Lymph node metastasis
Positive 38 (100) 53 (100) 1.000
Negative 0 (0) 0/0 (0)
Platinumepaclitaxel chemotherapy
Yes 31/33 (93.9) 48/52 (92.3) 1.000
No 2/33 (6.1) 4/52 (7.7)
Data are presented as n (%) or mean  SD. PSOC ¼ papillary serous ovarian
cancer; PSPC ¼ peritoneal serous papillary carcinoma.
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different from that for EOC [6e9].
A previous study suggested molecular similarities between
PSPC and EOC [10]. The recommended treatment for serous
PSPC is similar to that for serous ovarian carcinoma; however,
optimal cytoreductionmaybemoredifficult to achieve inwomen
with PSPC because of widespread peritoneal diseasewithout the
presence of a predominant pelvic or ovarian mass. Although it
has been shown to prolong survival, systemic chemotherapy in
the relapsed or refractory setting is not curative [11].
To date, most of the studies evaluating PSPC have focused
on western patients with high-grade serous tumors, with few
reports on PSPC in Asia. Several questions concerning the
management of EOC remain unclear. To study the prognosis
of patients with PSPC, we conducted a retrospective analysis
of cases treated in our institution and matched them with
a control group of patients with EOC. The aim of this study
was to evaluate the characteristics of patients with PSPC and
to analyze the survival of these patients in Taiwan.
Materials and methods
This study included 38 PSPC patients and 53 patients with
advanced-stage papillary serous ovarian cancer (PSOC) who
had been admitted, treated, and followed up at the Division of
Gynecologic Oncology, Department of Obstetrics and Gyne-
cology, Taipei Veterans General Hospital, Taiwan, between
January 2000 and December 2010. Approval for the study was
obtained from the hospital’s ethics committee. The patients
were selected on the basis of available histological material.
The histological specimens were reviewed by a gynecological
pathologist. Pathological specimens were assessed using the
WHO criteria for histological subtype and nuclear grade.
The following clinical information was obtained directly
from patients’ hospital records: date of birth, date of diagnosis,
operative findings, International Federation of Gynecology
and Obstetrics (FIGO) stage based on the clinical examination
and surgical exploration together with cytology results, cancer
antigen 125 (CA125) levels at diagnosis and relapse, date of
relapse, date of last follow-up, and date and cause of death.
The 38 advanced-stage PSPC patients had undergone
debulking surgery. Optimal debulking surgery was defined as
the presence of a residual tumor <1 cm in size after the pro-
cedure. By contrast, if the residual tumor was 1 cm, the sur-
gery was then defined as suboptimal debulking. There was no
significant difference in the optimal debulking rate between
advanced-stage PSPC and PSOC patients (Table 1). Of the 33
PSPC who underwent chemotherapy, 31 (93.9%) were treated
with six cycles of platinumepaclitaxel combination chemo-
therapy 2e3weeks after initial surgery. Therewas no significant
difference in the rate of platinumepaclitaxel chemotherapy
between the PSPC and PSOC patients (Table 1). The chemo-
therapy regimen consisted of paclitaxel plus cisplatin or pacli-
taxel plus carboplatin. The PSOC patients were treated with six
cycles of cisplatin-based combination chemotherapy (minimum
total dose of cisplatin, 400 mg/m2) 2e3 weeks after their initial
surgery. Cisplatin-based combination chemotherapy consistedof either the CP regimen (cyclophosphamide plus cisplatin) or
the CAP regimen (cisplatin, Adriamycin, and cyclo-
phosphamide). After completing treatment, most patients were
reviewed every 3e6 months for 5 years and annually thereafter.Statistical analysisThe various clinicopathological parameters were analyzed
by Fisher’s exact test and the c2 test. Progression-free survival
(PFS) was calculated from the date of surgery to the date of
relapse or the date last seen, and overall survival (OS) was
calculated from the date of diagnosis to the date of death or the
date last seen. Survival curves were plotted using the
KaplaneMeier method. Statistical differences in survival be-
tween the groups were compared using the log-rank test.
Statistical significance was set at p < 0.05.
Results
The mean age of patients with PSPC (63.03  11.88 years)
was significantly greater than for patients with PSOC
(55.92  12.56 years, p ¼ 0.008). Some 31 (81.6%) of the
PSPC patients had stage IIIc and seven (18.4%) had stage IV
disease. Of the PSOC patients, 46 (86.8%) had stage IIIc and
seven (13.2%) had stage IV disease (Table 1). All of the PSPC
patients had grade 3 tumors, but only 28 (68.3%) of the PSOC
patients had grade 3 tumors ( p < 0.001) (Table 1).
The rate of optimal debulking surgery was 71.9% in the
PSPC group and 66.0% in the PSOC but the difference was not
significant ( p ¼ 0.575; Table 1). Survival curves were plotted
using the KaplaneMeier method. PFS in the PSPC group
[median 12 months, 95% confidence interval (CI) 7.3e16.7]
Fig. 1. Progression-free survival curves for peritoneal serous papillary carci-
noma (PSPC) and papillary serous ovarian cancer (PSOC). PFS for PSPC
patients (median 12 months, 95% confidence interval 7.3e16.7) was similar to
that for PSOC patients (median 16.7 months, 95% confidence interval
12.9e20.4; p ¼ 0.470).
83K.-C. Chao et al. / Taiwanese Journal of Obstetrics & Gynecology 52 (2013) 81e84was similar to that in the PSOC group (median 16.7 months,
95% CI 12.9e20.4; p ¼ 0.470, log-rank statistic; Fig. 1). OS
was shorter in the PSPC group (median 62 months, 95% CI
19.6e104.4) than in the PSOC group (median 77.5 months,
95% CI 69.7e85.2; p ¼ 0.006, log-rank statistic; Fig. 2).
Discussion
Primary peritoneal carcinoma (PPC) is a malignancy with
diffuse involvement of the peritoneal surfaces while sparing orFig. 2. Overall survival (OS) curves for peritoneal serous papillary carcinoma
(PSPC) and papillary serous ovarian cancer (PSOC). OS in the PSPC group
(median 62 months, 95% confidence interval 19.6e104.4) was shorter than in
the POSC group (median 77.5 months, 95% confidence interval 69.7e85.2;
p ¼ 0.006, log-rank statistic).minimally involving the ovaries [12]. It is histologically
indistinguishable from EOC and has similar clinical charac-
teristics, patterns of spreading, response to treatment, and
survival rates [6,8,13]. Previous reports have suggested that
women with PPC have epidemiological features similar to
those of women with EOC, with the exception of an older age
at diagnosis and a higher rate of obesity [14]. We found similar
results. In our study, patients with PSPC were older than those
with PSOC.
According to a recent study, the median age at diagnosis of
low-grade PPC was 51.7 years (range 27.1e82.4) [15].
Among the 46 patients (86.8%) who underwent primary sur-
gery, optimal tumor reduction was achieved in 30 (65.2%).
Some 48 patients (90.6%) received chemotherapy as part of
their initial treatment. On completion of their primary treat-
ment, 66.7% of patients had persistent or progressive disease.
With a median follow-up of 66.1 months, the 5-year PFS was
16%, yet the 5-year OS was 69%. Similar to patients with low-
grade serous ovarian carcinoma, patients with low-grade se-
rous PPC have high rates of persistent disease on completion
of primary treatment, despite a long OS [15]. However, in our
study, PSPC was associated with a higher tumor grade in every
case.
The recommended treatment for serous PPC is similar to
that for serous ovarian carcinoma; however, optimal cytor-
eduction may be more difficult to achieve in women with PPC
because of widespread peritoneal disease without the presence
of a predominant pelvic or ovarian mass [9].
Cytoreductive surgery followed by combined platinum and
taxane chemotherapy is the accepted standard treatment for
patients with advanced EOC [16]. Three large randomized
Phase III studies comparing intraperitoneal (IP) to intravenous
(IV) cisplatin-based chemotherapy for patients with small-
volume residual disease reported favorable survival results
for IP intervention [17,18]. Furthermore, pharmacological data
now show that more than two-thirds of free platinum enters the
systemic circulation after IP carboplatin administration.
Miyagi et al demonstrated that the area under the curve (AUC)
for 24-hour free platinum in serum was identical for IP and IV
administration [19]. Concentrations may be even higher in
retroperitoneal lymph nodes [20]. Thus, in future work, we
will study the role of the IP regimen in treating PSPC.
This retrospective case-matched comparison confirms that
PFS in patients with PSPC is similar to that in patients with
advanced-stage PSOC. Chiou et al reported similar results
[21]. Therefore, the therapeutic response to debulking surgery
and platinumepaclitaxel chemotherapy may well be similar
for these two diseases. However, the OS for patients with
PSPC was poor compared to that for POSC patients. The
possibility of poor OS increases with age and the rate of poor
tumor grade is higher in PSPC. Thus, management of PSPC
should not be different from that of advanced-stage POSC.
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